Machiels Jean-Pascal, Lambrecht Maarten, Hanin François-Xavier, Duprez Thierry, Gregoire Vincent, Schmitz Sandra, Hamoir Marc
Clinique de cancérologie cervico-maxillo-faciale, Centre du cancer et d'hématologie, Cliniques universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (IREC), Université catholique de Louvain 10 Avenue Hippocrate, 1200 Brussels Belgium.
F1000Prime Rep. 2014 Jun 2;6:44. doi: 10.12703/P6-44. eCollection 2014.
Squamous cell carcinoma of the head and neck (SCCHN) is the sixth most common cancer worldwide. The main risk factors for cancers of the oral cavity, larynx, oropharynx, and hypopharynx are alcohol and tobacco use. In addition, the human papillomavirus (HPV) is an established cause of oropharyngeal cancer. An experienced multidisciplinary team is necessary for adequate management and optimal outcome. The treatment of locally advanced disease generally requires various combinations of radiotherapy, surgery, and systemic therapy, but despite this aggressive multimodal treatment, 40% to 60% of the patients will relapse. In this report, we will discuss recent advances in the management of SCCHN, including new developments in molecular biology, imaging, and treatment.
头颈部鳞状细胞癌(SCCHN)是全球第六大常见癌症。口腔、喉、口咽和下咽癌的主要危险因素是饮酒和吸烟。此外,人乳头瘤病毒(HPV)是口咽癌的确切病因。为了进行充分的管理并取得最佳结果,需要一个经验丰富的多学科团队。局部晚期疾病的治疗通常需要放疗、手术和全身治疗的各种组合,但尽管采用了这种积极的多模式治疗,仍有40%至60%的患者会复发。在本报告中,我们将讨论头颈部鳞状细胞癌管理方面的最新进展,包括分子生物学、影像学和治疗方面的新进展。